Keryx Biopharmaceuticals Announces Poster Presentations of KRX-0401 (Perifosine) at the 52nd Annual Meeting of the American Society of Hematology
NEW YORK, Dec. 2, 2010 /PRNewswire/ — Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that multiple abstracts for KRX-0401 (perifosine) have been selected for poster presentation at the upcoming 52nd Annual Meeting of the American Society of Hematology (ASH), to be held in Orlando, Florida from December 4-7, 2010.
Saturday, December 4, 5:30-7:30 p.m. (Hall A3/A4)
Abstract Number: 1842 (Poster Board I-822)
Abstract Title: “Pre-Clinical and Interim Results of a Phase II Trial of Perifosine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)”
First Author: Daphne R. Friedman, MD, Duke University Medical Center, Durham, NC
Sunday, December 5, 6:00 PM-8:00 PM (Hall A3/A4)
Abstract Number: 2861 (Poster Board II-741)
Abstract Title: “Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial”
First Author: Carmelo Carlo-Stella, MD, Fondazione IRCCS Istituto Nazionale Tumori and University of Milano, Milano, Italy
Abstract Number: 3064 (Poster Board II-944)
Abstract Title: “Final Phase I Results of Perifosine in Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)”
First Author: Andrzej Jakubowiak, MD, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
Monday, December 6, 6:00 PM-8:00 PM
Abstract Number: 3911 (Poster Board III-690)
Abstract Title: “Perifosine Affects Phenotype and Function of Human Myeloid Dendritic Cells”
First Author: Weihua Song, MD, Dana-Farber Cancer Institute, Boston, MA
A copy of the above referenced abstracts can be viewed online through the ASH website, www.hematology.org.
KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401 (perifosine); the risk that the data (both safety and efficacy) from ongoing clinical trials will not coincide with the data analyses from prior pre-clinical and clinical trials previously reported by the Company; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website and the ASH website is not incorporated by reference into this press release and is included for reference purposes only.
KERYX CONTACT: Lauren Fischer Director - Investor Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965 E-mail: email@example.com
SOURCE Keryx Biopharmaceuticals, Inc.